Limits...
Resveratrol possesses protective effects in a pristane-induced lupus mouse model.

Wang ZL, Luo XF, Li MT, Xu D, Zhou S, Chen HZ, Gao N, Chen Z, Zhang LL, Zeng XF - PLoS ONE (2014)

Bottom Line: To date, no therapy has been found to satisfactorily treat SLE.Resveratrol also suppressed CD69 and CD71 expression on CD4+ T cells as well as CD4+ T cell proliferation, induced CD4+ T cell apoptosis, and decreased CD4 IFNγ+ Th1 cells and the ratio of Th1/Th2 cells in vitro.In vitro antibody production and proliferation of B cells were also inhibited.

View Article: PubMed Central - PubMed

Affiliation: Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China.

ABSTRACT

Background: Systemic lupus erythematosus (SLE) is a multisystemic autoimmune disease characterized by the production of autoantibodies. To date, no therapy has been found to satisfactorily treat SLE. SIRT1 deficiency results in the development of an autoimmune syndrome in mice, including a high titer of anti-nuclear antibody in serum, immunoglobulin deposition in the kidney, and immune complex glomerulonephritis. Resveratrol is an activator of SIRT1 and possesses anti-inflammation and immune-regulatory properties.

Objective: To evaluate the preventative effects of resveratrol on a pristane-induced lupus animal model and assess its putative immune modulation effects.

Methods: BALB/c mice received a single intraperitoneal injection of 0.5 ml of pristane on day 1 and then various doses of resveratrol were given to the mice daily starting on day 2 and continuing for seven months. The autoantibodies in serum and supernatants were measured. Single cells isolated from spleen, isolated CD4+ T cells, and CD19+ B cells were cultured with or without resveratrol in vitro and assessed by flow cytometry.

Results: Resveratrol attenuated proteinuria, immunoglobuin depositon in kidney, and glomerulonephritis as well as IgG1 and IgG2a in serum in pristane-induced lupus mice. Resveratrol also suppressed CD69 and CD71 expression on CD4+ T cells as well as CD4+ T cell proliferation, induced CD4+ T cell apoptosis, and decreased CD4 IFNγ+ Th1 cells and the ratio of Th1/Th2 cells in vitro. In vitro antibody production and proliferation of B cells were also inhibited.

Conclusion: Resveratrol possesses protective effects in pristane-induced lupus mice and may represent a novel approach for the management of SLE.

Show MeSH

Related in: MedlinePlus

The effect of resveratrol on the subset of T helper cells.(A): Resveratrol inhibits CD4 IFNγ+ Th1 cells in a dose-dependent manner. (B): Resveratrol has no effect on CD4 IL-4+ Th2 cells. (C): Resveratrol decreases the ratio of Th1/Th2 cells in a dose-dependent manner. (D): Resveratrol had no effect on CD4 IFNγ−IL-17+ Th17 cells. (mean ± SD; n = 6, ★: P<0.05).
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4263676&req=5

pone-0114792-g007: The effect of resveratrol on the subset of T helper cells.(A): Resveratrol inhibits CD4 IFNγ+ Th1 cells in a dose-dependent manner. (B): Resveratrol has no effect on CD4 IL-4+ Th2 cells. (C): Resveratrol decreases the ratio of Th1/Th2 cells in a dose-dependent manner. (D): Resveratrol had no effect on CD4 IFNγ−IL-17+ Th17 cells. (mean ± SD; n = 6, ★: P<0.05).

Mentions: Freshly isolated SMCs were activated with PMA and ionomycine after having been cultured with resveratrol (0, 20, 40, or 80 µM) for 2 h to investigate Th1, Th2, and Th17+ cell populations by flow cytometry. We found that CD4 IFNγ+ Th1 cells decreased after treatment with resveratrol in a dose-dependent manner (P<0.05; Fig. 7A), although resveratrol had no effect on CD4 IL-4+Th2 cells or CD4 IFNγ−IL-17+ Th17 cells (Fig. 7B, Fig. 7D, respectively). Importantly, we found that the ratio of Th1/Th2 cells (CD4 IL-4+Th2) decreased after treatment with resveratrol in a dose-dependent manner (P<0.05; Fig. 7C),


Resveratrol possesses protective effects in a pristane-induced lupus mouse model.

Wang ZL, Luo XF, Li MT, Xu D, Zhou S, Chen HZ, Gao N, Chen Z, Zhang LL, Zeng XF - PLoS ONE (2014)

The effect of resveratrol on the subset of T helper cells.(A): Resveratrol inhibits CD4 IFNγ+ Th1 cells in a dose-dependent manner. (B): Resveratrol has no effect on CD4 IL-4+ Th2 cells. (C): Resveratrol decreases the ratio of Th1/Th2 cells in a dose-dependent manner. (D): Resveratrol had no effect on CD4 IFNγ−IL-17+ Th17 cells. (mean ± SD; n = 6, ★: P<0.05).
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4263676&req=5

pone-0114792-g007: The effect of resveratrol on the subset of T helper cells.(A): Resveratrol inhibits CD4 IFNγ+ Th1 cells in a dose-dependent manner. (B): Resveratrol has no effect on CD4 IL-4+ Th2 cells. (C): Resveratrol decreases the ratio of Th1/Th2 cells in a dose-dependent manner. (D): Resveratrol had no effect on CD4 IFNγ−IL-17+ Th17 cells. (mean ± SD; n = 6, ★: P<0.05).
Mentions: Freshly isolated SMCs were activated with PMA and ionomycine after having been cultured with resveratrol (0, 20, 40, or 80 µM) for 2 h to investigate Th1, Th2, and Th17+ cell populations by flow cytometry. We found that CD4 IFNγ+ Th1 cells decreased after treatment with resveratrol in a dose-dependent manner (P<0.05; Fig. 7A), although resveratrol had no effect on CD4 IL-4+Th2 cells or CD4 IFNγ−IL-17+ Th17 cells (Fig. 7B, Fig. 7D, respectively). Importantly, we found that the ratio of Th1/Th2 cells (CD4 IL-4+Th2) decreased after treatment with resveratrol in a dose-dependent manner (P<0.05; Fig. 7C),

Bottom Line: To date, no therapy has been found to satisfactorily treat SLE.Resveratrol also suppressed CD69 and CD71 expression on CD4+ T cells as well as CD4+ T cell proliferation, induced CD4+ T cell apoptosis, and decreased CD4 IFNγ+ Th1 cells and the ratio of Th1/Th2 cells in vitro.In vitro antibody production and proliferation of B cells were also inhibited.

View Article: PubMed Central - PubMed

Affiliation: Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China.

ABSTRACT

Background: Systemic lupus erythematosus (SLE) is a multisystemic autoimmune disease characterized by the production of autoantibodies. To date, no therapy has been found to satisfactorily treat SLE. SIRT1 deficiency results in the development of an autoimmune syndrome in mice, including a high titer of anti-nuclear antibody in serum, immunoglobulin deposition in the kidney, and immune complex glomerulonephritis. Resveratrol is an activator of SIRT1 and possesses anti-inflammation and immune-regulatory properties.

Objective: To evaluate the preventative effects of resveratrol on a pristane-induced lupus animal model and assess its putative immune modulation effects.

Methods: BALB/c mice received a single intraperitoneal injection of 0.5 ml of pristane on day 1 and then various doses of resveratrol were given to the mice daily starting on day 2 and continuing for seven months. The autoantibodies in serum and supernatants were measured. Single cells isolated from spleen, isolated CD4+ T cells, and CD19+ B cells were cultured with or without resveratrol in vitro and assessed by flow cytometry.

Results: Resveratrol attenuated proteinuria, immunoglobuin depositon in kidney, and glomerulonephritis as well as IgG1 and IgG2a in serum in pristane-induced lupus mice. Resveratrol also suppressed CD69 and CD71 expression on CD4+ T cells as well as CD4+ T cell proliferation, induced CD4+ T cell apoptosis, and decreased CD4 IFNγ+ Th1 cells and the ratio of Th1/Th2 cells in vitro. In vitro antibody production and proliferation of B cells were also inhibited.

Conclusion: Resveratrol possesses protective effects in pristane-induced lupus mice and may represent a novel approach for the management of SLE.

Show MeSH
Related in: MedlinePlus